Interactions

Active ingredient Amprenavir interacts in the following cases:

Hypericum perforatum (St John's Wort)

Hepatic failure stage IV
and additionally
Ritonavir

Antacids

Vitamin K antagonists

Calcium channel blockers

HMG CoA reductase inhibitors

Corticosteroid drugs

CYP2D6 substrates
and additionally
Ritonavir

CYP3A4 substrates

Hepatic insufficiency

at least one of
Carbamazepine

Phenobarbital

Phenytoin

at least one of
Ciclosporin

Tacrolimus

Methadone

Midazolam

Rifabutin

Rifampicin
and additionally
Ritonavir

at least one of
Sildenafil

Vardenafil

Pregnancy

There are no adequate data from the use of amprenavir in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown.

This medicinal product should be used during pregnancy only after careful weighing of the potential benefits compared to the potential risk to the foetus.

Nursing Mothers

Amprenavir-related material was found in rat milk, but it is not known whether amprenavir is excreted in human milk. A reproduction study in pregnant rats dosed from the time of uterine implantation through lactation showed reduced body weight gains in the offspring during the nursing period. The systemic exposure to the dams associated with this finding was similar to exposure in humans, following administration of the recommended dose. The subsequent development of the offspring, including fertility and reproductive performance, was not affected by the maternal administration of amprenavir.

Effects on Ability to Drive and Use Machines

No studies on the effects on ability to drive and use machines have been performed.